After earning his MD at Copenhagen University, following a completed internship, Kenneth worked as a clinician in paediatrics and Neurology.
He holds a Ph.D. in neuroscience from Copenhagen University. He brings 20 years of experience in preclinical and clinical drug development as well as business development. He has previously held positions at NatImmune, Novo Nordisk, and Lundbeck.

He founded Hoba Therapeutics in 2017 with seed investment from Novo Holdings and Borean Innovation.